A Phase 2 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Xiidra® (5% lifitegrast ophthalmic solution) in Dry Eye, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 2, and was the 7th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6
First in 2017; this study’s year is marked. 4 started in 2021.
This study's enrollment of 56 is close to the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 158 across the 11 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 2, and was the 9th registered.
Aldeyra Therapeutics, Inc.’s Dry Eye Syndromes studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Aldeyra Therapeutics, Inc.’s 13 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry Eye Disease in a Dry Eye Chamber
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose
Drug: Reproxalap Ophthalmic Solution (0.25%)
Single dose
Drug: Xiidra® (5% lifitegrast ophthalmic solution)
Reproxalap Ophthalmic Solution (0.25%) dosed once
Xiidra® (5% lifitegrast ophthalmic solution) dosed once
Change From Baseline in Ocular Discomfort
Ocular discomfort (0 = none, 10 = extremely severe) was reported by patients in a dry eye chamber. Change from baseline was analyzed using a mixed model repeated measures (MMRM) analysis, with baseline as a covariate, and treatment and intra-chamber time point as factors.
Time frame: The efficacy assessment period was approximately every 5 minutes during a 45-minute dry eye chamber. Baseline was prior to dosing for each treatment period.
Change From Baseline in Ocular Itching
Ocular itching (0 = none, 10 = extremely severe) was reported by patients in a dry eye chamber. Change from baseline was analyzed using a MMRM analysis, with baseline as a covariate, and treatment and intra-chamber time point as factors.
Time frame: The efficacy assessment period was approximately every 5 minutes during a 45-minute dry eye chamber. Baseline was prior to dosing for each treatment period.
| Milestone | Lifitegrast, Reproxalap |
|---|---|
| Started | 56 |
| Completed | 54 |
| Not completed | 2 |
Ocular discomfort (0 = none, 10 = extremely severe) was reported by patients in a dry eye chamber. Change from baseline was analyzed using a mixed model repeated measures (MMRM) analysis, with baseline as a covariate, and treatment and intra-chamber time point as factors.
| score on a scale | Reproxalap | Lifitegrast |
|---|---|---|
| Change From Baseline in Ocular Discomfort | 1.35 ± 0.21 | 2.07 ± 0.25 |
Ocular itching (0 = none, 10 = extremely severe) was reported by patients in a dry eye chamber. Change from baseline was analyzed using a MMRM analysis, with baseline as a covariate, and treatment and intra-chamber time point as factors.
| score on a scale | Reproxalap | Lifitegrast |
|---|---|---|
| Change From Baseline in Ocular Itching | 0.93 ± 0.21 | 1.54 ± 0.25 |
Collected over One day for each intervention. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reproxalap | 0/54 (0%) | 0/54 (0%) | 40/54 (74.1%) |
| Lifitegrast | 0/56 (0%) | 0/56 (0%) | 12/56 (21.4%) |
| Event | Reproxalap | Lifitegrast |
|---|---|---|
| General DisordersGeneral disorders | 40/54 | 6/56 |
| Nervous System DisordersNervous system disorders | 0/54 | 6/56 |
Enrolled subjects
| Age, Continuous(years) | Lifitegrast, Reproxalap |
|---|---|
| Mean | 47.9 ± 12.4 |
| Sex: Female, Male(Participants) | Lifitegrast, Reproxalap |
|---|---|
| Female | 36 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | Lifitegrast, Reproxalap |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 47 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Lifitegrast, Reproxalap |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 12 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 33 |
| More than one race | 5 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2021 to primary completion in Oct 2021, 1 month.
Results were first posted in Feb 2025, 3 years 4 months after primary completion. A results delay was requested in Sep 2022.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 1 month is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap